Antiobesity Global Market Report 2025

Description

Anti-obesity drugs are pharmaceutical substances used to regulate or reduce a patient's weight. These drugs impact fundamental bodily functions related to weight control, targeting either appetite or calorie absorption. While diet and exercise remain the primary therapies for managing weight in overweight and obese individuals, anti-obesity drugs offer a supplementary option.

The key categories of anti-obesity drugs consist of peripherally acting anti-obesity medications and centrally acting anti-obesity medications. Peripherally acting anti-obesity drugs facilitate weight loss without affecting the brain or appetite. They work by inhibiting pancreatic lipase and impeding fat breakdown in the gastrointestinal tract, consequently reducing fat absorption in the intestine. These drugs are available in various forms, including prescription drugs (Rx) and over-the-counter (OTC) medications, offering both monotherapies and combination therapies to address weight management.

The anti-obesity market research report is one of a series of new reports from The Business Research Company that provides anti-obesity market statistics, including anti-obesity industry global market size, regional shares, competitors with an anti-obesity market share, detailed anti-obesity market segments, market trends and opportunities, and any further data you may need to thrive in the anti-obesity industry. This anti-obesity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiobesity market size has grown rapidly in recent years. It will grow from $3.74 billion in 2024 to $4.15 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to increasing obesity prevalence, awareness and education, lifestyle changes, government initiatives.

The antiobesity market size is expected to see rapid growth in the next few years. It will grow to $6.08 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to market expansion, globalization. Major trends in the forecast period include research and development, patient-centric approaches, insurance coverage, technological advancements, digital health and telemedicine, novel drug therapies, bariatric surgery advancements, otc (over-the-counter) solutions, behavioral interventions, nutritional and weight management apps.

Obesity is a significant global public health issue, with its prevalence increasing each year. For example, a May 2022 report from the World Obesity Atlas, a UK-based organization focused on obesity, projected that by 2030, more than 1 billion individuals worldwide are expected to be affected by obesity. This alarming trend can be attributed to the growing consumption of processed and unhealthy foods, decreased physical activity levels, and a lack of awareness regarding the risks associated with obesity. Consequently, the demand for anti-obesity drugs is poised to rise in the future, driven by the urgent need to address this global health concern and support individuals in their weight management efforts. This growing demand is expected to contribute to the expansion of the anti-obesity drug market.

The increasing geriatric population is expected to drive the growth of the anti-obesity drugs market in the future. The geriatric population encompasses older individuals, typically aged 65 and above, and obesity remains a prevalent and significant concern within this age group. Elderly individuals, especially those with diabetes, are particularly susceptible to obesity due to reduced physical activity and impaired circulation. For example, in October 2022, reports from the World Health Organization, a specialized US-based health agency, indicated that globally, one in six individuals will be 60 years or older by 2030. Furthermore, by 2050, the number of individuals in this age group is projected to double, reaching approximately 2.1 billion. Consequently, the growing geriatric population is a significant driver of the anti-obesity drugs market, as it addresses the specific needs of older individuals in managing obesity and related health issues.

Major companies in the anti-obesity drugs market are dedicated to innovation, with a focus on developing new products to better serve their customers. One such innovative product is Mounjaro (tirzepatide), an anti-obesity drug designed to address the needs of adults with obesity or overweight conditions, particularly those with weight-related comorbidities. For example, in October 2022, Eli Lilly and Company, a US-based pharmaceutical company, launched Mounjaro (tirzepatide), which received fast track designation approval from the Food and Drug Administration (FDA), a US-based federal agency. Mounjaro (tirzepatide) is an injectable anti-obesity drug that aims to assist individuals struggling with obesity in achieving their weight loss goals. It is indicated for use in adults with type 2 diabetes and, when combined with a diet and exercise regimen, can help improve blood sugar (glucose) control. This type of innovation demonstrates the commitment of these companies to providing effective solutions for individuals grappling with obesity and related health issues.

The pharmaceutical industry is currently experiencing a growing trend of mergers and acquisitions among companies specializing in drug development for metabolic disorders, which encompass conditions like obesity and diabetes. This strategic approach is adopted by pharmaceutical companies to bolster their drug portfolios in the field of metabolic diseases and to introduce safe and efficacious medications to the market. For example, companies like Evotec AG and Novo Nordisk have established a strategic alliance to collaborate on the discovery and development of drug molecules designed to treat metabolic disorders. These disorders include obesity, diabetes, and related health conditions. Such collaborations and partnerships represent an effort to pool resources, expertise, and innovation in the quest to bring novel and effective drugs to individuals dealing with metabolic disorders, thereby addressing a significant health challenge.

Major companies operating in the antiobesity market include F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.

North America was the largest region in the anti-obesity market in 2024. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antiobesity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-obesity market consists of sales of liraglutide, semaglutide, naltrexone-bupropion, and orlistat. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antiobesity Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiobesity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antiobesity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antiobesity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Peripherally Acting Anti-Obesity Drugs; Centrally Acting Anti-Obesity Drugs
2) By Type: Prescription Drugs (Rx); OTC Drugs
3) By Medication: Monotherapies; Polytherapies
Subsegments:
1) By Peripherally Acting Anti-Obesity Drugs: Orlistat; Lorcaserin
2) By Centrally Acting Anti-Obesity Drugs: Phentermine; Topiramate; Naltrexone-Bupropion Combination; Liraglutide
Companies Mentioned: F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Boehringer Ingelheim GmbH; Pfizer Inc.; Merck & Co. Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r32386

1. Executive Summary

2. Antiobesity Market Characteristics

3. Antiobesity Market Trends And Strategies

4. Antiobesity Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Antiobesity Growth Analysis And Strategic Analysis Framework

5.1. Global Antiobesity PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Antiobesity Market Growth Rate Analysis
5.4. Global Antiobesity Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Antiobesity Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Antiobesity Total Addressable Market (TAM)

6. Antiobesity Market Segmentation

6.1. Global Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peripherally Acting Anti-Obesity Drugs
Centrally Acting Anti-Obesity Drugs
6.2. Global Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prescription Drugs (Rx)
OTC Drugs
6.3. Global Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapies
Polytherapies
6.4. Global Antiobesity Market, Sub-Segmentation Of Peripherally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Orlistat
Lorcaserin
6.5. Global Antiobesity Market, Sub-Segmentation Of Centrally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Phentermine
Topiramate
Naltrexone-Bupropion Combination
Liraglutide

7. Antiobesity Market Regional And Country Analysis

7.1. Global Antiobesity Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Antiobesity Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antiobesity Market

8.1. Asia-Pacific Antiobesity Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antiobesity Market

9.1. China Antiobesity Market Overview
9.2. China Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antiobesity Market

10.1. India Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antiobesity Market

11.1. Japan Antiobesity Market Overview
11.2. Japan Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antiobesity Market

12.1. Australia Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antiobesity Market

13.1. Indonesia Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antiobesity Market

14.1. South Korea Antiobesity Market Overview
14.2. South Korea Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antiobesity Market

15.1. Western Europe Antiobesity Market Overview
15.2. Western Europe Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antiobesity Market

16.1. UK Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antiobesity Market

17.1. Germany Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antiobesity Market

18.1. France Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antiobesity Market

19.1. Italy Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antiobesity Market

20.1. Spain Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antiobesity Market

21.1. Eastern Europe Antiobesity Market Overview
21.2. Eastern Europe Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antiobesity Market

22.1. Russia Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antiobesity Market

23.1. North America Antiobesity Market Overview
23.2. North America Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antiobesity Market

24.1. USA Antiobesity Market Overview
24.2. USA Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antiobesity Market

25.1. Canada Antiobesity Market Overview
25.2. Canada Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antiobesity Market

26.1. South America Antiobesity Market Overview
26.2. South America Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antiobesity Market

27.1. Brazil Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antiobesity Market

28.1. Middle East Antiobesity Market Overview
28.2. Middle East Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antiobesity Market

29.1. Africa Antiobesity Market Overview
29.2. Africa Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Antiobesity Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antiobesity Market Competitive Landscape And Company Profiles

30.1. Antiobesity Market Competitive Landscape
30.2. Antiobesity Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Antiobesity Market Other Major And Innovative Companies

31.1. Takeda Pharmaceutical Company Limited
31.2. Eisai Co. Ltd.
31.3. Novo Nordisk A/S
31.4. Zafgen Inc.
31.5. Rhythm Pharmaceuticals Inc.
31.6. Zydus Cadila
31.7. Norgine B.V.
31.8. Vivus Inc.
31.9. Arena Pharmaceuticals Inc.
31.10. Orexigen Therapeutics Inc.
31.11. Eli Lilly and Company
31.12. Amgen Inc.
31.13. AstraZeneca PLC
31.14. Novartis International AG
31.15. Viking Therapeutics Inc.

32. Global Antiobesity Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antiobesity Market

34. Recent Developments In The Antiobesity Market

35. Antiobesity Market High Potential Countries, Segments and Strategies

35.1 Antiobesity Market In 2029 - Countries Offering Most New Opportunities
35.2 Antiobesity Market In 2029 - Segments Offering Most New Opportunities
35.3 Antiobesity Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer